Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Molecular Templates (NASDAQ:MTEM) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $...
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early ...
Molecular Templates (NASDAQ:MTEM) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $...
- SEC Filing
-SEC Filing
Molecular Templates shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients...
